Literature DB >> 33194054

Combined treatment with anlotinib and chemotherapy for advanced esophageal squamous cell carcinoma improved patient survival: a case report.

Dongyang Yang1, Fei Xu1, Xiaorong Lai1, Ying Li1, Huibing Gao1, Ying Xu2, Rongrong Chen3, Dong Ma1.   

Abstract

Esophageal squamous cell carcinoma (ESCC) is the predominant type of esophageal cancer in Eastern Asia. Historically, advanced ESCC treatments have had low efficacy and new treatments, including immunotherapy or combination therapies, are emerging. Here, we report a special case of recurrent ESCC after surgery. The patient had a failed immunotherapy course, but benefited from anlotinib combined with chemotherapy for a fourth-line therapy. Survival after the combined therapy was greater than 19 months, and the overall patient survival was greater than 32 months. AJTR
Copyright © 2020.

Entities:  

Keywords:  Esophageal squamous cell carcinoma; anlotinib; chemotherapy

Year:  2020        PMID： 33194054      PMCID： PMC7653628     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN： 1943-8141            Impact factor:   4.060


  19 in total

1.  Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma.

Authors:  Madhavi Challa-Malladi; Yen K Lieu; Olivia Califano; Antony B Holmes; Govind Bhagat; Vundavalli V Murty; David Dominguez-Sola; Laura Pasqualucci; Riccardo Dalla-Favera
Journal:  Cancer Cell       Date:  2011-12-01       Impact factor: 31.743

Review 2.  Anlotinib: First Global Approval.

Authors:  Yahiya Y Syed
Journal:  Drugs       Date:  2018-07       Impact factor: 9.546

Review 3.  Epidemiology of Esophageal Squamous Cell Carcinoma.

Authors:  Christian C Abnet; Melina Arnold; Wen-Qiang Wei
Journal:  Gastroenterology       Date:  2017-08-18       Impact factor: 22.682

4.  Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

Authors:  Weiyi Peng; Jie Qing Chen; Chengwen Liu; Shruti Malu; Caitlin Creasy; Michael T Tetzlaff; Chunyu Xu; Jodi A McKenzie; Chunlei Zhang; Xiaoxuan Liang; Leila J Williams; Wanleng Deng; Guo Chen; Rina Mbofung; Alexander J Lazar; Carlos A Torres-Cabala; Zachary A Cooper; Pei-Ling Chen; Trang N Tieu; Stefani Spranger; Xiaoxing Yu; Chantale Bernatchez; Marie-Andree Forget; Cara Haymaker; Rodabe Amaria; Jennifer L McQuade; Isabella C Glitza; Tina Cascone; Haiyan S Li; Lawrence N Kwong; Timothy P Heffernan; Jianhua Hu; Roland L Bassett; Marcus W Bosenberg; Scott E Woodman; Willem W Overwijk; Gregory Lizée; Jason Roszik; Thomas F Gajewski; Jennifer A Wargo; Jeffrey E Gershenwald; Laszlo Radvanyi; Michael A Davies; Patrick Hwu
Journal:  Cancer Discov       Date:  2015-12-08       Impact factor: 39.397

Review 5.  Current status of cancer immunotherapy for esophageal squamous cell carcinoma.

Authors:  Koji Kono; Kousaku Mimura; Reo Yamada; Daisuke Ujiie; Suguru Hayase; Takeshi Tada; Hiroyuki Hanayama; Aung Kyi Thar Min; Masahiko Shibata; Tomoyuki Momma; Zenichirou Saze; Shinji Ohki
Journal:  Esophagus       Date:  2017-11-27       Impact factor: 4.230

6.  Anlotinib is effective in the treatment of advanced carcinoma ex pleomorphic adenoma of the submandibular gland.

Authors:  Shujie Song; Ping Sui; Minmin Li; Liangming Zhang; Dengjun Sun
Journal:  Onco Targets Ther       Date:  2019-05-24       Impact factor: 4.147

Review 7.  Combination of checkpoint inhibitors with radiotherapy in esophageal squamous cell carcinoma treatment: A novel strategy.

Authors:  Xiu-Yong Liao; Chao-Yuan Liu; Jian-Feng He; Li-Shu Wang; Tao Zhang
Journal:  Oncol Lett       Date:  2019-09-19       Impact factor: 2.967

8.  Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities.

Authors:  Ruidi Jiao; Hui Luo; Wenbo Xu; Hong Ge
Journal:  Onco Targets Ther       Date:  2019-07-29       Impact factor: 4.147

9.  A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma.

Authors:  Yong Tang; Zhu'an Ou; Zhifang Yao; Guibin Qiao
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.889

10.  A case report of primary osteosarcoma originating from kidney.

Authors:  Changkun Huang; Xuan Zhu; Wei Xiong; Xiaokun Zhao; Ran Xu
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817
View more
  2 in total

1.  Case report of penile cancer recurrence treated with cetuximab combined with anlotinib.

Authors:  Shuang Dai; Yan-Yang Liu; Tao Liu; Yu Zhang; De-Yun Luo
Journal:  Clin Case Rep       Date:  2022-02-15

2.  Anlotinib Inhibits Tumor Angiogenesis and Promotes the Anticancer Effect of Radiotherapy on Esophageal Cancer through Inhibiting EphA2.

Authors:  Zhenlin Gu; Weiguo Zhu; Wanwei Wang; Yingying Xu; Lei Jiang; Jiasheng Huang; Jing Huang
Journal:  J Oncol       Date:  2022-08-31       Impact factor: 4.501
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.